Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026

Feb.05
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.

 

Key Takeaways

 

  • Etomidate has been listed as a Class C drug under the Misuse of Drugs Act since Sept 1, 2025, amid increased reports of etomidate-laced vapes (Kpods) used by youths.
  • Temporary provisions were slated to expire on Feb 28, 2026; Shanmugam said the listing will continue while MOH drafts amendments.
  • A Bill will be tabled in Parliament in the first half of 2026 to tackle the e-vaporiser issue, with provisions also covering etomidate.
  • Non-etomidate vapes are policed under the Tobacco (Control of Advertisements and Sale) Act, with HSA as the lead agency.
  • MOH and HSA reported 3,534 people caught and fined for owning and using vapes in the last four months of 2025, including 366 Kpod abusers.

 


 

2Firsts, February 5, 2026

 

According to The Straits Times, Singapore will extend temporary drug control measures that classify the anaesthetic agent etomidate as a Class C drug, while finalising broader legislative amendments aimed at addressing the use and trade of e-vaporisers.

 

Coordinating Minister for National Security and Home Affairs Minister K. Shanmugam said etomidate would continue to be regulated under the Misuse of Drugs Act (MDA) as the Ministry of Health prepares amendments to existing laws. A Bill is expected to be tabled in Parliament in the first half of 2026, he said in a written parliamentary reply cited by the newspaper.

 

Etomidate was placed under the MDA from Sept 1, 2025, following a rise in cases involving young people vaping etomidate-laced pods, commonly known as Kpods, The Straits Times reported. The temporary provisions, which allow for tougher penalties against abusers and traffickers, were originally due to expire on Feb 28, 2026.

 

Prior to the reclassification, etomidate had been regulated under the Poisons Act as a medicinal ingredient used in clinical settings. Authorities have warned that inhalation through vaping can cause serious adverse effects, including spasms, breathing difficulties and seizures.

 

Non-etomidate e-vaporisers are currently enforced under the Tobacco (Control of Advertisements and Sale) Act, with the Health Sciences Authority (HSA) acting as the lead agency. The HSA told The Straits Times that Singapore’s strict anti-vaping stance would remain unchanged.

 

Under existing law, individuals who import, distribute or sell e-vaporisers may face fines of up to S$10,000 or up to six months’ imprisonment for a first offence, with higher penalties for repeat offences. In contrast, offences involving etomidate-laced vapes under the MDA carry significantly heavier sentences, including multi-year imprisonment and caning.

 

The HSA said it regularly reviews sentencing frameworks and considers factors such as the number of devices involved, whether the offence is commercial in nature, and the potential public health impact when determining enforcement action, according to the report.

 

Image Source: The Straits Times

Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13